Adjuvants to enhance cellular immune response to vaccines
Increase the effectiveness of human vaccines against infectious diseases such as COVID-19
15 Jun 2020
As a global life science supplier, Merck offers researchers, developers and manufacturers the necessary products and services to aid both the detection of Covid-19 and the development of vaccines and therapies. In particular, Avanti® Adjuvants offer unique applications to immunotherapy and vaccine development as have been shown to safely and effectively induce immune responses to heterologous proteins in animal and human vaccines.
Vaccination is well accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in the failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization.
Because vaccine adjuvants using Lipid A have been shown to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD®), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.
Read how Merck is collaborating with Baylor College of Medicine to scale up the manufacturing capacity of two Covid-19 vaccine candidates and accelerate their progression and availability for use in clinical trials in this article.
Do you use Merck products in your lab? Write a review today for your chance to win a $400 Amazon Gift Card>>
